SCHEMBL3449200

SCHEMBL3449200

CC(C)(CCCCBr)OC(N)=O

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27745506 0.98 LMNA (0.32) LMNAHSD17B10
SCHEMBL27734679 0.98 LMNA (0.32) LMNAHSD17B10
SCHEMBL3075338 0.94 LMNA (0.34) LMNAHSD17B10
SCHEMBL27696459 0.82 FDPS (0.36) LMNAHSD17B10
SCHEMBL27403746 0.82 LMNA (0.42) LMNAHSD17B10
SCHEMBL3203563 0.82 CYP4F2 (0.43) LMNAHSD17B10
SCHEMBL28320076 0.82 SOAT1 (0.34) LMNAHSD17B10
SCHEMBL9222465 0.82 GAA (0.43)
SCHEMBL29637097 0.80 SMPD1 (0.42) LMNAHSD17B10
SCHEMBL9225460 0.80 GAA (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103665329-B A kind of biotin functionalized soluble conjugated polymer and its preparation method and application NANJING POST & TELECOMMUNICATION UNIV. (CN) 2015-10-28 CN claimed
CN-103665329-A Biotin functionalized water-soluble conjugated polymer as well as preparation method and application thereof UNIV NANJING POSTS & TELECOMM 2014-03-26 CN claimed
CN-106164072-B Monocyclic lactam organic compounds for the treatment of bacterial infections 诺华股份有限公司 2019-10-01 CN disclosed
US-10208062-B2 Macrocyclic quinazole derivatives and their use as MTKI JANSSEN PHARMACEUTICA NV (BE) 2019-02-19 US disclosed
US-20170320894-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN PHARMACEUTICA NV (BE) 2017-11-09 US disclosed
US-9688691-B2 Macrocyclic quinazole derivatives and their use as MTKI JANSSEN PHARMACEUTICA NV (BE) 2017-06-27 US disclosed
CN-106164072-A Monocyclic lactam organic compounds for the treatment of bacterial infections 诺华股份有限公司 2016-11-23 CN disclosed
EP-1828201-B1 MACROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS MTKI JANSSEN PHARMACEUTICA NV (BE) 2015-11-11 EP disclosed
CN-103665329-B A kind of biotin functionalized soluble conjugated polymer and its preparation method and application NANJING POST & TELECOMMUNICATION UNIV. (CN) 2015-10-28 CN disclosed
US-20140256714-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 US disclosed
CN-103665329-A Biotin functionalized water-soluble conjugated polymer as well as preparation method and application thereof UNIV NANJING POSTS & TELECOMM 2014-03-26 CN disclosed
CN-101951913-A Poly aromatic sodium channel blockers PARION SCIENCES INC 2011-01-19 CN disclosed
US-20100152174-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN-CILAG (FR) 2010-06-17 US disclosed
CN-1764650-B 2, 3, 6-trisubstituted-4-pyrimidone derivatives MITSUBISHI PHARMA CORP 2010-06-16 CN disclosed
CN-101525339-A Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB 2009-09-09 CN disclosed
CN-101243093-A New oxabispidine compounds for the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2008-08-13 CN disclosed
EP-1828201-A2 MACROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS MTKI JANSSEN PHARMACEUTICA N.V. (BE) 2007-09-05 EP disclosed
CN-1968956-A Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2007-05-23 CN disclosed
WO-2006061417-A2 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-15 WO disclosed
CN-1764650-A 2, 3, 6-trisubstituted-4-pyrimidone derivatives MITSUBISHI PHARMA CORP (JP) 2006-04-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256714-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI NR1I3, NR3C2, NR1I2 LMNA 3140/4885HSD17B10 385/4885
US-20100152174-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI NR1I3, NR1I2, NR3C2 LMNA 3597/4885HSD17B10 217/4885
US-20170320894-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI NR1I3, NR3C2, NR1I2 LMNA 3140/4885HSD17B10 385/4885
US-10208062-B2 Macrocyclic quinazole derivatives and their use as MTKI NR1I3, NR3C2, NR1I2 LMNA 3140/4885HSD17B10 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.